Bevacizumab
Withdrawn from marketPreviously used for Ovarian Epithelial Carcinoma.
Also known as Alymsys, Avastin, Avzivi, Jobevne+5 more
Alymsys, Avastin, Avzivi, Jobevne, Mvasi, Vegzelma, Zirabev, rhuMAb VEGF, rhuMAb-VEGF.
Recent clinical, regulatory, research and industry developments relating to this drug.
Approval: BEVACIZUMAB-VIKG (BLA761320)
Market withdrawal: Lextemy (EMA)
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Lytenava is indicated in adults for treatment of neovascular (wet) age-related macular degeneration (nAMD).
Evidence ↗Indication: Treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and… Show full indicationShow less
Treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- The New England journal of medicine9
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology6
- Clinical cancer research : an official journal of the American Association for Cancer Research2
- Autophagy1
- BMC gastroenterology1
- Cancer immunology, immunotherapy : CII1
- Modest DP3
- Tewari KS3
- Wang M3
- Bu X2
- Coleman RL2
- Colombo N2
- Dickler M2
- Elez E2
- German Cancer Research Center (DKFZ)2
- Ghent University Hospital2
- Mayo Clinic2
- Memorial Sloan Kettering Cancer Center2
- National Cancer Institute2
- Sarah Cannon Research Institute2
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 9 of the same disease areas as Bevacizumab in the shared literature.
Studied across 9 of the same disease areas as Bevacizumab in the shared literature.
Studied across 11 of the same disease areas as Bevacizumab in the shared literature.
Studied across 8 of the same disease areas as Bevacizumab in the shared literature.
Studied across 10 of the same disease areas as Bevacizumab in the shared literature.
Studied across 14 of the same disease areas as Bevacizumab in the shared literature.
Studied across 8 of the same disease areas as Bevacizumab in the shared literature.
Studied across 9 of the same disease areas as Bevacizumab in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- Europe PMC — research literature
- Regulatory event sources are credited in the Regulatory Timeline above.